Previous close | 0.2800 |
Open | N/A |
Bid | 0.0000 |
Ask | 1.3500 |
Strike | 155.00 |
Expiry date | 2025-01-17 |
Day's range | 0.2800 - 0.7000 |
Contract range | N/A |
Volume | |
Open interest | 1 |
– Continued enrollment globally in multiple clinical studies of vepdegestrant in ER+/HER2- metastatic breast cancer, including the VERITAC-2 Phase 3 trial in the second-line setting and the study lead-in for the VERITAC-3 Phase 3 trial in the first-line setting – – Top-line data readout for VERITAC-2 remains on-track for 2H 2024 – – Entered a transaction with Novartis providing an exclusive license for ARV-766 and sale of preclinical AR-V7 program; $150 million upfront payment and potential for
Alnylam (ALNY) reports better-than-expected first-quarter 2024 results as both earnings and revenues beat estimates, primarily driven by strong Amvuttra sales.
Novartis agreed to acquire U.S. radiopharmaceutical company Mariana Oncology for $1 billion upfront, boosting its portfolio of precision cancer treatments in development, the Swiss drug manufacturer said on Thursday. Mariana Oncology is working on novel radioligand cancer therapies (RLTs) that have not yet been tested on humans. "The transaction bolsters the Novartis RLT pipeline and expands the company’s research infrastructure and clinical supply capabilities," Novartis said in a statement.